Atrinsic Inc. (NASDAQ:PTIX – Get Free Report) shares were up 2.5% on Friday . The stock traded as high as $2.15 and last traded at $2.07. Approximately 56,058 shares were traded during trading, a decline of 96% from the average daily volume of 1,407,398 shares. The stock had previously closed at $2.02.
Analyst Ratings Changes
Separately, Wall Street Zen raised Atrinsic from a “sell” rating to a “hold” rating in a report on Saturday, September 13th.
Check Out Our Latest Research Report on Atrinsic
Atrinsic Stock Performance
Atrinsic (NASDAQ:PTIX – Get Free Report) last announced its quarterly earnings data on Wednesday, September 10th. The company reported ($1.37) EPS for the quarter.
About Atrinsic
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Featured Stories
- Five stocks we like better than Atrinsic
- How to find penny stocks to invest and trade
- A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
- Technology Stocks Explained: Here’s What to Know About Tech
- 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
- Bank Stocks – Best Bank Stocks to Invest In
- Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?
Receive News & Ratings for Atrinsic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrinsic and related companies with MarketBeat.com's FREE daily email newsletter.
